Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bd393d1ca55e33bf78739757a6698561d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bd393d1ca55e33bf78739757a6698561d NCIT_P378 "NCI" @default.
- Bd393d1ca55e33bf78739757a6698561d type Axiom @default.
- Bd393d1ca55e33bf78739757a6698561d annotatedProperty IAO_0000115 @default.
- Bd393d1ca55e33bf78739757a6698561d annotatedSource NCIT_C181916 @default.
- Bd393d1ca55e33bf78739757a6698561d annotatedTarget "The succinate salt form of mobocertinib, an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization." @default.